Polymer-Linked BPA Derivative for Boron Neutron Capture Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current boron drugs, such as BSH and BPA, face challenges in maintaining high tumor/normal tissue and tumor/blood boron concentration ratios due to poor solubility and early elimination from tumor cells, leading to inadequate boron retention for effective neutron capture therapy.
Innovation Solution
A p-boronophenylalanine derivative linked to a polymer, which is taken up by tumor cells via endocytosis through the amino acid transporter LAT1, allowing for prolonged intracellular boron retention and improved concentration ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BPA is administered to accumulate boron in tumors through LAT1 transporter, then tumor selectivity is improved, but intracellular boron is eliminated early due to exchange transporter mechanism
Solution Approach 1:
The patent modifies the molecular weight parameter of BPA by conjugating it with polymers (increasing from small molecule to macromolecule), which changes the uptake mechanism from LAT1 exchange transport to non-exchange pathways, thereby preventing early elimination while maintaining tumor selectivity
Solution Approach 2:
The patent creates composite structures by conjugating BPA with various polymers (PEG, polyvinyl alcohol, chitosan, etc.), forming polymer-BPA conjugates that combine the tumor-targeting capability of BPA with the prolonged circulation and retention properties of polymers
2Reliability
If third generation boron drugs use carriers with long term blood retention to achieve EPR effect, then tumor selectivity is improved, but tumor/blood boron concentration ratio decreases
Solution Approach 1:
The patent creates a dynamic system where polymer-BPA conjugates exhibit different behaviors in different compartments: they circulate in blood with sufficient stability to reach tumors, but are selectively taken up by tumor cells via endocytosis and retained intracellularly, achieving both high tumor/blood ratio and tumor selectivity
3Quantity of substance
If BPA concentration is maintained by continuous drip administration, then intratumoral boron concentration is maintained, but normal tissue radiation exposure increases
Solution Approach 1:
The polymer-BPA conjugates self-regulate their distribution: they passively accumulate in tumors through EPR effect and are actively taken up by tumor cells via endocytosis, creating a self-sustaining system that maintains intratumoral boron concentration without requiring continuous external administration, thereby reducing normal tissue exposure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer-linked BPA derivative achieves selective and long-term boron accumulation in tumors, maintaining high tumor/normal tissue and tumor/blood boron concentration ratios, enhancing the efficacy of boron neutron capture therapy.
Implementation Method 1
the phenylalanine structure of BPA is recognized by, for example, the amino acid transporter (LAT1), which is overexpressed in tumor cells, and BPA is selectively taken up by tumor cells
Implementation Method 2
a boron delivery system in which BPA is carried on a polymer is taken up by tumor cells by endocytosis via an amino acid transporter
Data Source
AI summary
The present invention pertains to: a p-boronophenylalanine derivative that comprises a polymer to which a group represented by formula (I) is linked directly or via a linker; a composition containing same; and a kit for producing said derivative and composition.